Results from 327 women demonstrated: Significant increases in satisfying sexual events compared to placebo at 1.25 mg and 1.75 mg doses Improved Female Sexual Function Index total scores (mean improvement of 3.6 points vs 1.9 for placebo) Reduced sexual distress as measured by Female Sexual Distress Scale scores Dose-dependent response with optimal effects at 1.75 mg Two Phase 3 trials (RECONNECT studies) enrolled over 1,200 premenopausal women with acquired, generalized HSDD and confirmed efficacy at the 1.75 mg dose administered subcutaneously at least 45 minutes before anticipated sexual activity
La semaglutida imita una hormona que acta sobre las zonas del cerebro que controlan el apetito, reduciendo el hambre y la ingesta de caloras
Drink at least 810 glasses daily
Bacteriostatic water helps reduce microbial growth, while sterile water contains no additives
Has the pharmacy received FDA warning letters or state-board actions
The MDL added 85 new suits in June, bringing the total number of cases to 3,848 as of July 1, 2026
